However, confirmation of efficacy through other in-vitro studies, including anti-aromatase activities, and different cytotoxic tests against breast cancer, in addition to in-vivo hormone-positive breast anti-tumor efficacy in athymic nude mice, are required to get more details on the anti-tumor activity of these two compounds against ER positive breast cancer cells. The gene discussed is CYP19A1; the disease is neoplasm.